Nauman Malik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nauman Malik has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Louie
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada
2 shared publications - Osama Mohamad
Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publications A. Gomes
Department of Speech Language Pathology, University of Toronto, Toronto, ON, Canada
1 shared publicationA.K. Paulsson
Providence Medical Group, Sonoma, CA
1 shared publicationAkbar Beiki-Ardakani
Princess Margaret Cancer Centre, University Health Network, Radiation Medicine Program, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada
1 shared publication- Alan Ayoub
Department of Emergency Medicine, University Hospital Dubrava, 10000 Zagreb, Croatia
1 shared publication
Latest Publications
- 23 February 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (4) , 892-893
Reirradiation After Incomplete Salvage in p16-Positive Oropharyngeal Carcinoma: How Far Should We Go?
- 23 February 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (4) , 892-893
Reirradiation After Incomplete Salvage in p16-Positive Oropharyngeal Carcinoma: How Far Should We Go?
- Open Access
- 28 October 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111239
Pain control and opioid use as a function of workflow in MRI-guided interstitial cervix brachytherapy
- 28 October 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111239
Open AccessPain control and opioid use as a function of workflow in MRI-guided interstitial cervix brachytherapy
- 29 December 2023
- Published by Elsevier in Brachytherapy
- Vol. 23 (2) , 173-178
Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series
- 29 December 2023
- Published by Elsevier in Brachytherapy
- Vol. 23 (2) , 173-178
Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series
- Open Access
- 29 September 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 117 (2) , e597
Impacts of Wildfire Events on California Radiation Oncology Clinics and Patients
- 29 September 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 117 (2) , e597
Open AccessImpacts of Wildfire Events on California Radiation Oncology Clinics and Patients
- Open Access
- 1 August 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (17) , 18133-18152
Factors influencing treatment decision‐making for cancer patients in low‐ and middle‐income countries: A scoping review
Purpose: In this scoping review, we evaluated existing literature related to factors influencing treatment decision‐making for patients diagnosed with cancer in low‐ and middle‐income countries, noting factors that influence decisions to pursue treatment with curative versus non‐curative intent. We identified an existing framework for adult cancer developed in a high‐income country (HIC) context and described similar and novel factors relevant to low‐and middle‐income country settings.Methods: We used scoping review methodology to identify and synthesize existing literature on factors influencing decision‐making for pediatric and adult cancer in these settings. Articles were identified through an advanced Boolean search across six databases, inclusive of all article types from inception through July 2022.Results: Seventy‐nine articles were identified from 22 countries across six regions, primarily reporting the experiences of lower‐middle and upper‐middle‐income countries. Included articles largely represented original research (54%), adult cancer populations (61%), and studied patients as the targeted population (51%). More than a quarter of articles focused exclusively on breast cancer (28%). Approximately 30% described factors that influenced decisions to choose between therapies with curative versus non‐curative intent. Of 56 reported factors, 22 novel factors were identified. Socioeconomic status, reimbursement policies/cost of treatment, and treatment and supportive care were the most commonly described factors.Conclusions: This scoping review expanded upon previously described factors that influence cancer treatment decision‐making in HICs, broadening knowledge to include perspectives of low‐ and middle‐income countries. While global commonalities exist, certain variables influence treatment choices differently or uniquely in different settings. Treatment regimens should further be tailored to local environments with consideration of contextual factors and accessible resources that often impact decision‐making.
- 1 August 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (17) , 18133-18152
Open AccessFactors influencing treatment decision‐making for cancer patients in low‐ and middle‐income countries: A scoping review
Purpose: In this scoping review, we evaluated existing literature related to factors influencing treatment decision‐making for patients diagnosed with cancer in low‐ and middle‐income countries, noting factors that influence decisions to pursue treatment with curative versus non‐curative intent. We identified an existing framework for adult cancer developed in a high‐income country (HIC) context and described similar and novel factors relevant to low‐and middle‐income country settings.Methods: We used scoping review methodology to identify and synthesize existing literature on factors influencing decision‐making for pediatric and adult cancer in these settings. Articles were identified through an advanced Boolean search across six databases, inclusive of all article types from inception through July 2022.Results: Seventy‐nine articles were identified from 22 countries across six regions, primarily reporting the experiences of lower‐middle and upper‐middle‐income countries. Included articles largely represented original research (54%), adult cancer populations (61%), and studied patients as the targeted population (51%). More than a quarter of articles focused exclusively on breast cancer (28%). Approximately 30% described factors that influenced decisions to choose between therapies with curative versus non‐curative intent. Of 56 reported factors, 22 novel factors were identified. Socioeconomic status, reimbursement policies/cost of treatment, and treatment and supportive care were the most commonly described factors.Conclusions: This scoping review expanded upon previously described factors that influence cancer treatment decision‐making in HICs, broadening knowledge to include perspectives of low‐ and middle‐income countries. While global commonalities exist, certain variables influence treatment choices differently or uniquely in different settings. Treatment regimens should further be tailored to local environments with consideration of contextual factors and accessible resources that often impact decision‐making.
- 11 August 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 114 (1) , 14
Whose Neck Is on the Line?
- 11 August 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 114 (1) , 14
Whose Neck Is on the Line?
- 19 December 2021
- Published by Wiley in Head & Neck
- Vol. 44 (3) , 770-782
Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review
Management of locoregionally advanced head and neck cancers (HNCs) remains a challenge. Some groups have attempted to use stereotactic radiotherapy (SBRT) to deliver “boost” treatment following conventional radiotherapy to improve local control (LC) and overall survival (OS), while aiming for acceptable toxicities. Medline, EMBASE, and Cochrane Library databases were queried for SBRT as curative‐intent planned boost in HNC after conventional radiotherapy. Individual studies were reviewed from inception until January 2021, extracting patient, treatment, and outcome data. Nine studies met inclusion criteria, representing 454 unique patients treated with curative intent across multiple head and neck sites with conventional radiotherapy. At 3 years, median LC was 92% (90%–98%), and median OS was 80% (75%–91%). Seven treatment‐related grade 5 toxicities (1.5%) were reported. Despite acceptable LC and OS rates, there were severe treatment‐related late toxicities. As such, SBRT boost should only be used in investigational settings until more data is available.
- 19 December 2021
- Published by Wiley in Head & Neck
- Vol. 44 (3) , 770-782
Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review
Management of locoregionally advanced head and neck cancers (HNCs) remains a challenge. Some groups have attempted to use stereotactic radiotherapy (SBRT) to deliver “boost” treatment following conventional radiotherapy to improve local control (LC) and overall survival (OS), while aiming for acceptable toxicities. Medline, EMBASE, and Cochrane Library databases were queried for SBRT as curative‐intent planned boost in HNC after conventional radiotherapy. Individual studies were reviewed from inception until January 2021, extracting patient, treatment, and outcome data. Nine studies met inclusion criteria, representing 454 unique patients treated with curative intent across multiple head and neck sites with conventional radiotherapy. At 3 years, median LC was 92% (90%–98%), and median OS was 80% (75%–91%). Seven treatment‐related grade 5 toxicities (1.5%) were reported. Despite acceptable LC and OS rates, there were severe treatment‐related late toxicities. As such, SBRT boost should only be used in investigational settings until more data is available.
- 27 June 2020
- Published by Springer Nature in Journal of Cancer Education
- Vol. 37 (1) , 203-209
Mapping the Current State of Canadian Medical School Oncology Interest Groups
Cancer is the leading cause of mortality in Canada. Undergraduate medical education therefore must ensure adequate oncology education for all physicians and inspire some to make oncology their career specialty, in an effort to ensure public care needs are met in the future. Medical student-led oncology interest groups (OIGs) are a subset of specialty interest groups that supplement formal didactic and clinical learning to increase exposure to oncology and access to mentors. We conducted a survey of OIG leaders to ascertain their goals, activities, barriers, future directions, and perceptions about employment prospects. OIG leaders from 12/17 Canadian medical schools responded. Medical oncology was the most represented specialty in OIGs. Half of OIGs had faculty mentors. Self-reported goals were to increase exposure to oncology disciplines (n = 12), assist students with career selection (n = 11) and finding mentors (n = 7), and enhance oncology education (n = 10). OIGs held on average 5 events per year (range 1–12). Reported barriers were finding time to plan events, declining student interest over academic year, and limited funding. Many OIGs showed interest in more standardized resources about oncology disciplines (n = 9), access to presentations (n = 10), more funding (n = 7), and collaboration (n = 7). Employment in many oncology specialties was perceived poorly, and the most important career selection considerations were ease of employment, practice location, and partner/family preference. Our survey highlights common goals, barriers, and perceptions in OIG medical student leaders across Canada and provides guidance for future interventions.
- 27 June 2020
- Published by Springer Nature in Journal of Cancer Education
- Vol. 37 (1) , 203-209
Mapping the Current State of Canadian Medical School Oncology Interest Groups
Cancer is the leading cause of mortality in Canada. Undergraduate medical education therefore must ensure adequate oncology education for all physicians and inspire some to make oncology their career specialty, in an effort to ensure public care needs are met in the future. Medical student-led oncology interest groups (OIGs) are a subset of specialty interest groups that supplement formal didactic and clinical learning to increase exposure to oncology and access to mentors. We conducted a survey of OIG leaders to ascertain their goals, activities, barriers, future directions, and perceptions about employment prospects. OIG leaders from 12/17 Canadian medical schools responded. Medical oncology was the most represented specialty in OIGs. Half of OIGs had faculty mentors. Self-reported goals were to increase exposure to oncology disciplines (n = 12), assist students with career selection (n = 11) and finding mentors (n = 7), and enhance oncology education (n = 10). OIGs held on average 5 events per year (range 1–12). Reported barriers were finding time to plan events, declining student interest over academic year, and limited funding. Many OIGs showed interest in more standardized resources about oncology disciplines (n = 9), access to presentations (n = 10), more funding (n = 7), and collaboration (n = 7). Employment in many oncology specialties was perceived poorly, and the most important career selection considerations were ease of employment, practice location, and partner/family preference. Our survey highlights common goals, barriers, and perceptions in OIG medical student leaders across Canada and provides guidance for future interventions.
- Open Access
- 1 October 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 139, S61-S62
142 Does a Rocky Treatment Course in Head & Neck Cancer Patients Predict Oncologic Outcomes?
- 1 October 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 139, S61-S62
Open Access142 Does a Rocky Treatment Course in Head & Neck Cancer Patients Predict Oncologic Outcomes?
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E378
Pre-treatment Class Attendance and Outcomes in Head & Neck Cancer Patients Undergoing Radiation
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E378
Pre-treatment Class Attendance and Outcomes in Head & Neck Cancer Patients Undergoing Radiation